AccessibilityHelpAbout Us
Aspen Pharmacare logo

Aspen Pharmacare(OTC) APNHF

Market Cap$3.83BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)+133%
5 Year-6%
1 Year+25%
1 Month+2%
$8.90
+0.00%
+0.00Today
Aspen Pharmacare last closing stock price
MetricPriceDate
Last closeUSD 8.902026-08-14
Aspen Pharmacare stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.3%USD 8.702026-07-31
1 month+2.25%USD 8.702026-06-29
3 month+2.25%USD 8.702026-05-05
Year to date+42.79%USD 6.232025-10-16
1 year+24.81%USD 7.132025-06-10
3 year+2.04%USD 8.722023-06-07
5 year-6.46%USD 9.512021-07-02
Since inception+132.94%USD 3.822008-05-12

Aspen Pharmacare Financials at a Glance

Market Cap

$3.83BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

ZAR 78.62B

Net Income (TTM)

ZAR 1.59B

EPS (TTM)

$0.35

P/E Ratio

25.27

Dividend

$0.12

Beta (Volatility)

0.12 (Low)

Price

$8.90

Volume

105

Open

$8.90

Previous Close

$8.90

Daily Range

$8.90 - $8.90

52-Week Range

$6.23 - $8.90

Estimated Earnings Date

Mar 11, 2027

APNHF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aspen Pharmacare

Aspen Pharmacare Holdings Limited is a global leader in the development, production, and distribution of specialized pharmaceutical products. The company operates primarily in two divisions: Commercial Pharmaceuticals and Manufacturing, offering a diverse range of products across various therapeutic areas.

Products and Services
  • Specialized anesthetics, including general anesthetics and muscle relaxants
  • Injectable anticoagulants under the Thrombosis brand
  • Branded consumer and prescription medications, such as Circadin and Maltofer
Growth Outlook
  • Recent quarterly revenue reached ZAR 18.3 billion, indicating strong market demand
  • Operating income margin improved to 12.9%, reflecting operational efficiency
  • Expansion into emerging markets is expected to drive future growth
Financial Highlights
  • Trailing twelve-month revenue of ZAR 69.5 billion, showcasing consistent performance
  • Net income margin of 7.6% demonstrates profitability despite market challenges
  • Dividend yield of 1.34% offers potential income for investors
Aspen Pharmacare Holdings Limited has established itself as a significant player in the pharmaceutical industry, with a focus on specialized products that cater to diverse medical needs. The company's commitment to innovation and expansion into new markets positions it well for future growth. Recent financial performance indicates a solid foundation, with increasing revenue and improving margins, making it an attractive option for potential investors. The diverse product portfolio and strategic focus on emerging markets further enhance its growth prospects.
AI Generated • Sep 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9,557

CEO

Stephen Bradley Saad, PhD

Website

www.aspenpharma.com

Headquarters

Durban, NL 4321, ZA

APNHF Financials

Key Financial Metrics (TTM)

Gross Margin

40.31%

Operating Margin

15.48%

Net Income Margin

7.59%

Return on Equity

3.28%

Return on Capital

5.73%

Return on Assets

2.44%

Earnings Yield

3.96%

Dividend Yield

1.38%

Payout Ratio

35.55%

Stock Overview

Market Cap

$3.83BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

430.69M

Volume

105

Avg. Volume

4.828

Financials (TTM)

Gross Profit

ZAR 33.32B

Operating Income

ZAR 8.51B

EBITDA

ZAR 10.06B

Operating Cash Flow

ZAR 12.10B

Capital Expenditure

-ZAR 4.74B

Free Cash Flow

ZAR 7.36B

Cash & ST Invst.

ZAR 15.76B

Total Debt

ZAR 15.34B

Aspen Pharmacare Performance Analysis

Aspen Pharmacare annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30ZAR 2,291,231,296-9.7%
20242024-06-30ZAR 2,388,834,3334.3%
20252025-06-30ZAR 2,387,723,936-0.0%
20262026-06-30ZAR 2,062,644,479-13.6%
Aspen Pharmacare sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-6.8%
Q42025-06-30-2.5%
Q22025-12-31-20.7%
Q42026-06-307.9%
Aspen Pharmacare annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30ZAR 0.66-29.6%
20242024-06-30ZAR 0.53-20.0%
20252025-06-30ZAR -0.13N/A
20262026-06-30ZAR 0.35N/A
Aspen Pharmacare sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31128.9%
Q42025-06-30-245.4%
Q22025-12-31142.3%
Q42026-06-30-17.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

ZAR 18.30B

-22.4%

Gross Profit

ZAR 6.79B

-32.8%

Gross Margin

37.11%

N/A

Market Cap

$3.83BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$400.90K

N/A

Employees

9,557

N/A

Net Income

ZAR 1.21B

+15.6%

EBITDA

ZAR 3.35B

-42.9%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

ZAR 15.76B

+27.8%

Total Debt

ZAR 15.34B

-57.9%

Accounts Receivable

ZAR 496.60M

-95.7%

Inventory

ZAR 13.78B

-23.4%

Long Term Debt

ZAR 9.36B

-62.8%

Short Term Debt

ZAR 5.98B

-47.1%

Return on Assets

2.44%

N/A

Return on Invested Capital

5.87%

N/A

Free Cash Flow

ZAR 2.34B

+10.8%

Operating Cash Flow

ZAR 3.39B

-9.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HYPMYHypera S.A.
$4.64-2.52%
CURLFCuraleaf Holdings, Inc.
$11.22-5.48%
MCRPFMicroPort Scientific Corporation
$0.85+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.35+83.85%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.63-0.09%
JAGXJaguar Health
$7.06-20.76%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$146.33+0.06%

Questions About APNHF

What is the current price of Aspen Pharmacare?

Aspen Pharmacare is trading at $8.90 per share.

What is the 52-week range for Aspen Pharmacare?

Over the past 52 weeks, Aspen Pharmacare has traded between $6.23 and $8.90.

How much debt does Aspen Pharmacare have?

As of the most recent reporting period, Aspen Pharmacare reported total debt of ZAR 949.91M.

How much cash does Aspen Pharmacare have on hand?

Aspen Pharmacare reported ZAR 976.08M in cash and cash equivalents in its most recent financial results.

What is Aspen Pharmacare’s dividend yield?

Aspen Pharmacare currently has a dividend yield of 1.38%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services